Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib PK Study with Gemfibrozil in Healthy Adults
NCT05868356Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Primary endpoints: Area Under the Curve, Maximum Plasma Concentration and 1 more. Started Jun 2023; status: completed.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05868356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868356.